Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles McTiernan
University of Pittsburgh at Pittsburgh, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Globin Solutions, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The investigator's conflict arises due to his financial interest in Globin Solutions, Inc. The company recently licensed nitrite salts intellectual property from the NIH and this intellectual property is being further evaluated/developed in animal research as part of this project. The investigator holds equity in this non-publicly traded company.
Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
PROJECT NARRATIVE In our tPPG, we have proposed that pulmonary vascular disease is a relatively under-studied, but important sub-phenotype in the broader setting of chronic heart and lung diseases, increasing disease severity and complicating therapy. Pathological pulmonary vascular remodeling occurs in subsets of patients in the setting of left heart diastolic dysfunction, the metabolic syndrome, and is a secondary event in advanced lung diseases. The development of pulmonary hypertension (PH) in these settings is further modulated by host genetics, diet, and microbiome and the development of the most effective specific therapy likely requires dual targeting of the underlying conditions, such as metabolic syndrome and the pulmonary vascular sub-phenotype. Based on extensive data generated over the last cycle of this tPPG, we hypothesize that new nitrate, nitrite, and nitro-fatty acid based therapies, that have now successfully advanced through human phase 1 safety testing, will target both the metabolic syndrome and the pulmonary vasculature, to limit disease progression in patients with this PH sub-phenotype.
Filed on August 08, 2019.
Tell us what you know about Charles McTiernan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Charles McTiernan”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles McTiernan | University of Pittsburgh at Pittsburgh | Conflict of Interest | Globin Solutions, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.